一組癌癥和影像學(xué)專家組成的國際小組，制定了一項(xiàng)評(píng)估淋巴瘤治療反應(yīng)的標(biāo)準(zhǔn)指南。該指南將為全球范圍的臨床醫(yī)生提供統(tǒng)一標(biāo)準(zhǔn)，用以比較和解釋淋巴瘤治療的臨床試驗(yàn)，從而推動(dòng)新治療措施的開發(fā)。

該新指南是由國際統(tǒng)一標(biāo)準(zhǔn)化項(xiàng)目(IHP)研發(fā)的，是根據(jù)1999年由包括臨床醫(yī)生、放射科醫(yī)生和病理學(xué)家組成的國際工作小組(IWG)制定的非何杰金淋巴瘤治療反應(yīng)評(píng)估標(biāo)準(zhǔn)而制定的。

PET是一種非侵入性影像技術(shù)，該技術(shù)利用了注射的化學(xué)示蹤劑發(fā)射出的放射活性。PET使用的放射示蹤劑最典型的是氟脫氧葡萄糖(FDG)，這是葡萄糖的放射性標(biāo)記形式，該物質(zhì)主要被腫瘤而不是正常組織所利用。

Guidelines Add PET for Evaluating Lymphoma Treatment
 
An international team of cancer and imaging specialists has developed standardized guidelines for assessing lymphoma response to treatment. The guidelines will provide clinicians worldwide with uniform criteria to compare and interpret clinical trials of lymphoma treatments and should facilitate the development of new therapies.

The new guidelines, developed by the International Harmonization Project (IHP), build on criteria for treatment response assessment of non-Hodgkin’s lymphoma published in 1999 by an international working group (IWG) of clinicians, radiologists, and pathologists.

PET is a non-invasive imaging technique that uses radioactivity emitted from injected tracer chemicals to measure and image biologic activity. The most typically used PET radiotracer is fluorodeoxyglucose (FDG), a radiolabeled form of glucose, which is consumed more avidly by tumors than by healthy tissue.